Principal Financial Group Inc. Sells 17,431 Shares of Illumina, Inc. $ILMN

Principal Financial Group Inc. decreased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 4.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 341,497 shares of the life sciences company’s stock after selling 17,431 shares during the quarter. Principal Financial Group Inc. owned about 0.22% of Illumina worth $32,432,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Empowered Funds LLC increased its holdings in shares of Illumina by 113.7% in the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC purchased a new position in shares of Illumina during the 2nd quarter valued at approximately $621,000. QRG Capital Management Inc. raised its position in shares of Illumina by 77.7% in the second quarter. QRG Capital Management Inc. now owns 7,450 shares of the life sciences company’s stock worth $711,000 after acquiring an additional 3,257 shares during the period. Wealthcare Advisory Partners LLC boosted its position in Illumina by 41.1% during the second quarter. Wealthcare Advisory Partners LLC now owns 8,916 shares of the life sciences company’s stock worth $851,000 after purchasing an additional 2,598 shares in the last quarter. Finally, Valeo Financial Advisors LLC lifted its position in shares of Illumina by 43.4% during the 2nd quarter. Valeo Financial Advisors LLC now owns 3,643 shares of the life sciences company’s stock valued at $348,000 after buying an additional 1,102 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q4 earnings beat — Illumina reported $1.35 GAAP/non‑GAAP EPS (beat consensus) and $1.16B in revenue (above estimates), showing 5% YoY revenue growth for the quarter. This confirms near‑term operating leverage and profitability. Zacks: Tops Q4 Estimates
• Positive Sentiment: FY2026 revenue guide lifted — Illumina gave 2026 revenue guidance of $4.5B–$4.6B (above Street revenue consensus), signaling expected mid-single-digit growth and underlying demand momentum. That revenue guide is a key upside catalyst for FY26. Press Release / Guidance
• Positive Sentiment: Operational tailwinds — Management highlighted clinical consumables growth, expansion into multiomics and margin momentum (non‑GAAP op margin guidance ~23.3–23.5%), supporting durable revenue mix improvement and higher-margin recurring revenue. Yahoo Deep Dive
• Neutral Sentiment: SomaLogic acquisition and dilution — Guidance includes ~$0.18 EPS dilution and ~100bps margin headwind from the recently closed SomaLogic deal; strategic for multiomics but a modest near‑term drag. PR Newswire: Financial Results
• Neutral Sentiment: Full call and disclosures available — The earnings call transcript, slide deck and SEC/press materials are posted for deeper review of segment trends and backlog — useful for modeling revenue cadence and margin drivers. Seeking Alpha Transcript
• Negative Sentiment: FY2025 revenue flat — Full-year 2025 revenue was essentially flat vs. 2024, a disappointment to some investors who had hoped for stronger recovery; this disappointment is the main reason shares are down despite the quarterly beat. Investing.com: Shares Tumble

Insider Buying and Selling at Illumina

In other news, insider Scott M. Davies sold 323 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the transaction, the insider owned 17,887 shares in the company, valued at $2,434,241.83. This trade represents a 1.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Guggenheim lifted their target price on shares of Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Illumina in a report on Monday, December 29th. JPMorgan Chase & Co. increased their target price on shares of Illumina from $105.00 to $130.00 and gave the stock a “neutral” rating in a report on Monday, December 15th. Robert W. Baird set a $109.00 price objective on Illumina in a research note on Friday, October 31st. Finally, UBS Group boosted their target price on shares of Illumina from $110.00 to $120.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Six analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Illumina currently has a consensus rating of “Hold” and a consensus price target of $127.18.

Illumina Stock Performance

NASDAQ:ILMN opened at $133.61 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. The firm has a market cap of $20.42 billion, a price-to-earnings ratio of 29.96, a price-to-earnings-growth ratio of 2.23 and a beta of 1.45. The firm’s fifty day moving average price is $138.67 and its 200 day moving average price is $115.99. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $155.53.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.26 by $0.09. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The firm’s revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.